Litigation Details for Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Docket		Date Filed	2018-11-08
Court	Court of Appeals for the Federal Circuit	Date Terminated	2020-03-16
Cause		Assigned To
Jury Demand		Referred To
Patents	7,407,955; 8,119,648; 8,178,541; 8,673,927; 8,853,156; 9,173,859
Link to Docket	External link to docket

Details for Boehringer Ingelheim v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2019-07-01	45		compound patent (U.S. Patent No. 7,407,955 or “the ’955 Patent”) and two method-of-treatment patents (U.S….S. Patent No. 8,178,541 or “the ’541 Patent” and U.S. Patent No. 8,119,648 or “the ’648 Patent”) for… its patent monopoly by obtaining three more serially-filed patents that add nothing patentable to its… ’541 Patent) and without metformin (the ’648 Patent). In an attempt to evergreen these patents, Boehringer…filed for U.S. Patent Nos. 9,173,859 (“the ’859 Patent”) and 8,673,927 (“the ’927 Patent”). Both claim	External link to document